Cellectar Biosciences initiates NCI-supported phase II trial of CLR 131 in MM
Cellectar Biosciences announces the initiation of a Phase II clinical study of its lead phospholipid drug conjugate CLR 131 in patients with multiple myeloma and other hematologic malignancies. The study will be conducted in up to 15 centers in the U.S.. March 30, 2017